Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study

By sjmartinez • March 30, 2025

Yoo C, Ueno M, Klümpen HJ, Kelley RK, Vogel A, Furuse J, Ren Z, Yau T, Chan SL, Ozaka M, Oh SC, Gu S, Park JO, Valle JW, Edeline J, Kim JG, Kamble S, Norquist JM, Yu L, Malhotra U, Finn RS. Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study. J Hepatol. 2025 Mar 26:S0168-8278(25)00207-7. doi: 10.1016/j.jhep.2025.03.019. Epub ahead of print. PMID: 40154623.

Tags: biliary tract neoplasms, cisplatin, gemcitabine, Hematology/Oncology, immune checkpoint inhibitors, Patient reported outcome measures, pembrolizumab, Publications, Quality of Life

Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma

Hecht JR, Oberoi A, Garralda Cabanas E, Jae Chon H, Digklia A, Rottey S, Martin Jimenez M, Chaney M, Hippenmeyer J, Lawrence T, Liu K,[...]

Biology, care, and outcomes of gestational breast cancers: a review

Duggirala N, Zhang S, Master A, Rao R, Kapoor NS, Bardia A, Lipsyc-Sharf M. Biology, care, and outcomes of gestational breast cancers: a review. Breast[...]

CRE25-032: Carfilzomib-Induced Thrombotic Microangiopathy in Multiple Myeloma

Bransky NP, Kathuria-Prakash N, Sehl M. CRE25-032: Carfilzomib-Induced Thrombotic Microangiopathy in Multiple Myeloma. J Natl Compr Canc Netw. 2025 Mar 28;23(3.5):CRE25-032. doi: 10.6004/jnccn.2024.7101. PMID: 40154331.